104PStudy of toxicity of the conventional treatments in myeloproliferative neoplasms, based on the functional status of the RUNX1/CBF-BETA/P300/HIPK2 complex

Background: Myeloproliferative neoplasms (MPNs) are clonal hematological malignancies with an inherent tendency to progress to acute leukemia, after a variable period of time. Although the mechanisms involved in the disease transformation are still unclear, it´s known that transcription factor RUNX1 (AML1) is frequently deregulated in human leukemia, and recently, it has been described that the activity of RUNX1 together with CBF-β cofactor is regulated by the proteins p300 and HIPK2. In fact, HIPK2 phosphorylates both RUNX1 and p300, activating the whole transcriptional complex. Therefore, the study of the status of this complex seems to be interesting in order to understand the mechanisms involved in the leukemic transformation.